Shots:

• Merck to acquire Arqule in all-cash transactions at $20/share- making a total deal value $2.7B. The transaction is expected to be completed in Q1’20
• The focus of the acquisition is to bolster Merck’s oncology pipeline with the addition of ArQule’s lead investigational candidate- ARQ 531- a precision therapy to treat hematological malignancies
• ArQule’s ARQ 531 (PO) is a novel BTK inhibitor- currently being evaluated in P-II dose-expansion study for the treatment of B-cell malignancies and has demonstrated safety and anti-tumor activity for the treatment of patients with r/r CLL and Richter’s Transformation in its early studies

Click here to­ read full press release/ article 

 Ref: Merck | Image: Merck